netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US

Result of AGM

Jun 4, 2021
-
News, RNS Announcements

NetScientific plc

(“NetScientific”, the “Group” or the “Company”)

Result of AGM

 

London, UK – 3 June 2021 – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that at its Annual General Meeting held today, all resolutions were duly passed.

 

Resolutions 1 to 6 were passed as Ordinary Resolutions and Resolution 7 was passed as a Special Resolution. Voting on all resolutions at the Annual General Meeting was conducted by poll and the results are as follows:

 

Resolution For % Against % Vote Total Vote Total as % of Issued Share Capital Withheld*
1.       To receive adopt the accounts of the Company for the period ended 31st December 2020 7,723,506 100.0% 0 0.0% 7,723,506 51.4% 625
2.       To approve the Directors’ Remuneration Report 7,065,213 88.7% 896,573 11.3% 7,724,119 51.4% 12
3.       To reappoint BDO LLP as auditors 7,723,506 100.0% 625 0.0% 7,724,131 51.4% 0
4.       To authorise Audit Committee Determining Auditors’ remuneration 7,723,308 100.0% 98 0.0% 7,723,406 51.4% 725
5.       To reappoint Clive Sparrow as director 7,723,089 100.0% 1,014 0.0% 7,724,103 51.4% 28
6.       To authorise the Directors to allot relevant securities pursuant to section 551 of the Companies Act 2006 7,722,989 100.0% 1,142 0.0% 7,724,131 51.4% 0
7.       To disapply pre-emption rights on the allotment of securities or sale of treasury shares in connection with a pre-emptive offer or on allotment of shares 7,717,622 99.9% 6,509 0.1% 7,724,131 51.4% 0

 

* A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes “For” or “Against” a resolution.

 

 

For more information, please contact:

NetScientific Via Walbrook PR
Ilian Iliev, CEO  
   
WH Ireland (NOMAD, Financial Adviser and Broker)  
Chris Fielding / Darshan Patel +44 (0)20 7220 1666
   
Walbrook PR  
Nick Rome/ Paul McManus/

Nicholas Johnson

07748 325 236, 07980 541 893

or 07884 664 686

 

About NetScientific

NetScientific plc (AIM: NSCI) is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally.

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, either through direct subsidiary, balance sheet investment or capital under advisory, varying from start-up private companies to publicly listed equities.

NetScientific delivers shareholder returns through a proactive and hands-on management approach to their portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group targets value inflection points and the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong transatlantic and growing international presence, providing attractive expansion prospects.

NSCI can deploy a capital-light investment structure; utilising the power of the PLC Brand, and the NetScientific balance sheet to anchor future investments and achieve a multiplier effect by attracting 3rd party investment for the portfolio companies.

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013 (website: www.netscientific.net).

 

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test 
NEXT POST →
TR-1: Holding(s) in Company

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
Copyright
Terms of Use
Result of AGM - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT